4D Molecular Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for 4D Molecular Therapeutics (FDMT).

Price Target Range — 11 Quarters

Analyst Consensus — 13 Analysts

12Buy

1Sell

Consensus RatingBuy# Analysts13Avg. Consensus PT$33Upside to Avg. PT+138.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 29, 2026	B of A Securities	Tazeen Ahmad	PT Raise	Buy	$29→$33
Sep 14, 2026	Cantor Fitzgerald	Josh Schimmer	Upgrade	Neutral→Overweight	$20
Jul 31, 2026	B. Riley Securities	Mayank Mamtani	Initiate	Buy	$37
Jul 20, 2026	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$36
Mar 30, 2026	Jefferies	Faisal Khurshid	Assumes	Buy	$40→$21
Mar 20, 2026	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$36
Mar 19, 2026	RBC Capital	Lisa Walter	PT Raise	Outperform	$32→$35
Mar 19, 2026	Chardan Capital	Geulah Livshits	Maintained	Buy	$26
Jan 28, 2026	Barclays	Eliana Merle	Initiate	Overweight	$33
Dec 18, 2025	Chardan Capital	Geulah Livshits	Maintained	Buy	$26
Nov 11, 2025	RBC Capital	Lisa Walter	PT Raise	Outperform	$26→$32
Nov 11, 2025	Barclays	Gena Wang	PT Cut	Overweight	$38→$33
Nov 11, 2025	Chardan Capital	Geulah Livshits	PT Raise	Buy	$25→$26
Oct 21, 2025	RBC Capital	Lisa Walter	Maintained	Outperform	$26
Aug 12, 2025	Roth Capital	Salveen Richter	PT Cut	Buy	$44→$38
Aug 12, 2025	Chardan Capital	Geulah Livshits	Maintained	Buy	$25
Aug 1, 2025	Chardan Capital	Geulah Livshits	Maintained	Buy	$25
Jul 3, 2025	Chardan Capital	Geulah Livshits	Maintained	Buy	$25
May 9, 2025	Chardan Capital	Geulah Livshits	PT Cut	Buy	$28→$25
May 9, 2025	Goldman Sachs	Salveen Richter	PT Cut	Buy	$51→$44

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
B of A Securities Maintains Buy on 4D Molecular Therapeutics, Raises Price Target to $33

B of A Securities analyst Tazeen Ahmad maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and raises the price target from $29 to $33.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Upgrades 4D Molecular Therapeutics to Overweight, Announces $20 Price Target

Cantor Fitzgerald analyst Josh Schimmer upgrades 4D Molecular Therapeutics (NASDAQ:FDMT) from Neutral to Overweight and announces $20 price target.

Benzinga Newsdesk

PRO
B. Riley Securities Initiates Coverage On 4D Molecular Therapeutics with Buy Rating, Announces Price Target of $37

B. Riley Securities analyst Mayank Mamtani initiates coverage on 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy rating and announces Price Target of $37.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and maintains $36 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and maintains $36 price target.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on 4D Molecular Therapeutics, Raises Price Target to $35

RBC Capital analyst Lisa Walter maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Outperform and raises the price target from $32 to $35.

Benzinga Newsdesk

4D Molecular Therapeutics Inc

4D Molecular Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
B of A Securities Maintains Buy on 4D Molecular Therapeutics, Raises Price Target to $33

PRO
Cantor Fitzgerald Upgrades 4D Molecular Therapeutics to Overweight, Announces $20 Price Target

PRO
B. Riley Securities Initiates Coverage On 4D Molecular Therapeutics with Buy Rating, Announces Price Target of $37

PRO
HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target

PRO
RBC Capital Maintains Outperform on 4D Molecular Therapeutics, Raises Price Target to $35

People Also Watch

People Also Watch

4D Molecular Therapeutics Inc

4D Molecular Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROB of A Securities Maintains Buy on 4D Molecular Therapeutics, Raises Price Target to $33

PROCantor Fitzgerald Upgrades 4D Molecular Therapeutics to Overweight, Announces $20 Price Target

PROB. Riley Securities Initiates Coverage On 4D Molecular Therapeutics with Buy Rating, Announces Price Target of $37

PROHC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target

PROHC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target

PRORBC Capital Maintains Outperform on 4D Molecular Therapeutics, Raises Price Target to $35

People Also Watch

People Also Watch

PRO
B of A Securities Maintains Buy on 4D Molecular Therapeutics, Raises Price Target to $33

PRO
Cantor Fitzgerald Upgrades 4D Molecular Therapeutics to Overweight, Announces $20 Price Target

PRO
B. Riley Securities Initiates Coverage On 4D Molecular Therapeutics with Buy Rating, Announces Price Target of $37

PRO
HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target

PRO
RBC Capital Maintains Outperform on 4D Molecular Therapeutics, Raises Price Target to $35